BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morgan SJ, Couch J, Guzzie-Peck P, Keller DA, Kemper R, Otieno MA, Schulingkamp RJ, Jones TW. Regulatory Forum Opinion Piece*: Use and Utility of Animal Models of Disease for Nonclinical Safety Assessment: A Pharmaceutical Industry Survey. Toxicol Pathol 2017;45:372-80. [PMID: 28351296 DOI: 10.1177/0192623317701004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Kakiuchi-Kiyota S, Schutten MM, Zhong Y, Crawford JJ, Dey A. Safety Considerations in the Development of Hippo Pathway Inhibitors in Cancers. Front Cell Dev Biol 2019;7:156. [PMID: 31475147 DOI: 10.3389/fcell.2019.00156] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
2 Tomohiro M, Okabe T, Kimura Y, Kinoshita K, Maeda M, Mitobe Y, Motoyama K, Yonezawa R, Sasaki S, Fujiwara M, Watanabe K. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper. Toxicol Pathol 2019;47:108-20. [PMID: 30636562 DOI: 10.1177/0192623318816669] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Yang B, Papoian T. Preclinical approaches to assess potential kinase inhibitor-induced cardiac toxicity: Past, present and future: PRECLINICAL APPROACHES AND KI-CARDIOTOXICITY. J Appl Toxicol 2018;38:790-800. [DOI: 10.1002/jat.3584] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
4 Blanset D, Hutt J, Morgan S. Current use of animal models of disease for nonclinical safety testing. Current Opinion in Toxicology 2020;23-24:11-6. [DOI: 10.1016/j.cotox.2020.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Authier S, Brock WJ, Halpern W, Harris SN, Jones D, McGovern T, McGovern PD, Pugsley MK. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey. Int J Toxicol 2021;40:487-505. [PMID: 34569357 DOI: 10.1177/10915818211043435] [Reference Citation Analysis]
6 Sura R, Hutt J, Morgan S. Opinion on the Use of Animal Models in Nonclinical Safety Assessment: Pros and Cons. Toxicol Pathol 2021;49:990-5. [PMID: 33827334 DOI: 10.1177/01926233211003498] [Reference Citation Analysis]
7 Hutt JA, Assaf BT, Bolon B, Cavagnaro J, Galbreath E, Grubor B, Kattenhorn LM, Romeike A, Whiteley LO. Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus Vectors. Toxicol Pathol 2021;:1926233211041962. [PMID: 34657529 DOI: 10.1177/01926233211041962] [Reference Citation Analysis]